_id
69147bb1ccc777a4e85d909c
Ticker
MREO
Name
Mereo BioPharma Group PLC ADR
Exchange
NASDAQ
Address
One Cavendish Place, London, United Kingdom, W1G 0QF
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.mereobiopharma.com
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Last Close
2.25
Volume
2004208
Current Price
2.17
Change
-3.555555555555559
Last Updated
2025-12-02T12:06:16.667Z
Image
data:image/webp;base64,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
Ipo Date
2019-04-24T00:00:00.000Z
Market Cap
292802336
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.75
Target Price
7.1256
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
1000
Gross Profit
-1000
Operating Expenses
10014000
Operating Income
-10015000
Interest Expense
28000
Pretax Income
-7024000
Net Income
-7024000
Eps
-0.0439029080188699
Dividends Per Share
-
Shares Outstanding
159131701
Income Tax Expense
-
EBITDA
-9815000
Operating Margin
-
Total Other Income Expense Net
2991000
Cash
48698000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
52407000
Property Plant Equipment
552000
Total Assets
53602000
Payables
879000
Short Term Debt
397000
Long Term Debt
-
Total Liabilities
7004000
Equity
46598000
Depreciation
-11000
Change In Working Capital
636000
Cash From Operations
-7309000
Capital Expenditures
0
Cash From Investing
300000
Cash From Financing
0
Net Change In Cash
-7427000
PE
-
PB
7.639306825400231
ROE
-15.0736083093695
ROA
-13.10398865713966
FCF
-7309000
Fcf Percent
-
Piotroski FScore
0
Health Score
34
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
1000
Quarters > 0 > income Statement > gross Profit
-1000
Quarters > 0 > income Statement > operating Expenses
10014000
Quarters > 0 > income Statement > operating Income
-10015000
Quarters > 0 > income Statement > interest Expense
28000
Quarters > 0 > income Statement > pretax Income
-7024000
Quarters > 0 > income Statement > net Income
-7024000
Quarters > 0 > income Statement > eps
-0.0439029080188699
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
159989402
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-9815000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2991000
Quarters > 0 > balance Sheet > cash
48698000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
52407000
Quarters > 0 > balance Sheet > property Plant Equipment
552000
Quarters > 0 > balance Sheet > total Assets
53602000
Quarters > 0 > balance Sheet > payables
879000
Quarters > 0 > balance Sheet > short Term Debt
397000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
7004000
Quarters > 0 > balance Sheet > equity
46598000
Quarters > 0 > cash Flow > net Income
-7024000
Quarters > 0 > cash Flow > depreciation
-11000
Quarters > 0 > cash Flow > change In Working Capital
636000
Quarters > 0 > cash Flow > cash From Operations
-7309000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
300000
Quarters > 0 > cash Flow > cash From Financing
0
Quarters > 0 > cash Flow > net Change In Cash
-7427000
Quarters > 0 > ratios > PE
-0.0439029080188699
Quarters > 0 > ratios > PB
7.639306825400231
Quarters > 0 > ratios > ROE
-15.0736083093695
Quarters > 0 > ratios > ROA
-13.10398865713966
Quarters > 0 > ratios > FCF
-7309000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
500000
Quarters > 1 > income Statement > cost Of Revenue
132000
Quarters > 1 > income Statement > gross Profit
368000
Quarters > 1 > income Statement > operating Expenses
10867000
Quarters > 1 > income Statement > operating Income
-10499000
Quarters > 1 > income Statement > interest Expense
24000
Quarters > 1 > income Statement > pretax Income
-14616000
Quarters > 1 > income Statement > net Income
-14616000
Quarters > 1 > income Statement > eps
-0.09141452379894194
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
159887066
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-14294000
Quarters > 1 > income Statement > operating Margin
-2099.8
Quarters > 1 > income Statement > total Other Income Expense Net
-4117000
Quarters > 1 > balance Sheet > cash
56125000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
3747000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
61421000
Quarters > 1 > balance Sheet > property Plant Equipment
740000
Quarters > 1 > balance Sheet > total Assets
62631000
Quarters > 1 > balance Sheet > payables
1138000
Quarters > 1 > balance Sheet > short Term Debt
601000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
8454000
Quarters > 1 > balance Sheet > equity
54177000
Quarters > 1 > cash Flow > net Income
-14616000
Quarters > 1 > cash Flow > depreciation
298000
Quarters > 1 > cash Flow > change In Working Capital
-843000
Quarters > 1 > cash Flow > cash From Operations
-7651000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-1521
Quarters > 1 > cash Flow > cash From Financing
-134000
Quarters > 1 > cash Flow > net Change In Cash
-6358000
Quarters > 1 > ratios > PE
-0.09141452379894194
Quarters > 1 > ratios > PB
6.566416040939883
Quarters > 1 > ratios > ROE
-26.97823799767429
Quarters > 1 > ratios > ROA
-23.336686305503665
Quarters > 1 > ratios > FCF
-7651000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-15.302
Quarters > 1 > health Score
27
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
271036
Quarters > 2 > income Statement > gross Profit
-271036
Quarters > 2 > income Statement > operating Expenses
11202000
Quarters > 2 > income Statement > operating Income
-11202000
Quarters > 2 > income Statement > interest Expense
180000
Quarters > 2 > income Statement > pretax Income
-12887000
Quarters > 2 > income Statement > net Income
-12887000
Quarters > 2 > income Statement > eps
-0.08215822222587171
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
156855877
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-12437000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-1685000
Quarters > 2 > balance Sheet > cash
62483000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
2398000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
66899000
Quarters > 2 > balance Sheet > property Plant Equipment
869000
Quarters > 2 > balance Sheet > total Assets
68322000
Quarters > 2 > balance Sheet > payables
2924000
Quarters > 2 > balance Sheet > short Term Debt
747000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
8241000
Quarters > 2 > balance Sheet > equity
60081000
Quarters > 2 > cash Flow > net Income
-12887000
Quarters > 2 > cash Flow > depreciation
270000
Quarters > 2 > cash Flow > change In Working Capital
-514000
Quarters > 2 > cash Flow > cash From Operations
-8329000
Quarters > 2 > cash Flow > capital Expenditures
320000
Quarters > 2 > cash Flow > cash From Investing
-320000
Quarters > 2 > cash Flow > cash From Financing
422000
Quarters > 2 > cash Flow > net Change In Cash
-7319000
Quarters > 2 > ratios > PE
-0.08215822222587171
Quarters > 2 > ratios > PB
5.808896761455369
Quarters > 2 > ratios > ROE
-21.449376674822325
Quarters > 2 > ratios > ROA
-18.862152747284917
Quarters > 2 > ratios > FCF
-8649000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1064260
Quarters > 3 > income Statement > cost Of Revenue
271459
Quarters > 3 > income Statement > gross Profit
-271459
Quarters > 3 > income Statement > operating Expenses
14861908
Quarters > 3 > income Statement > operating Income
-15133368
Quarters > 3 > income Statement > interest Expense
375000
Quarters > 3 > income Statement > pretax Income
-7551327
Quarters > 3 > income Statement > net Income
-6980668
Quarters > 3 > income Statement > eps
-0.04499430038643827
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
155145606
Quarters > 3 > income Statement > income Tax Expense
-570659
Quarters > 3 > income Statement > EBITDA
-6908343
Quarters > 3 > income Statement > operating Margin
-1421.9615507488772
Quarters > 3 > income Statement > total Other Income Expense Net
7582040
Quarters > 3 > balance Sheet > cash
69802000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
3250000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
74763000
Quarters > 3 > balance Sheet > property Plant Equipment
984000
Quarters > 3 > balance Sheet > total Assets
76390000
Quarters > 3 > balance Sheet > payables
2440000
Quarters > 3 > balance Sheet > short Term Debt
6242000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
15421000
Quarters > 3 > balance Sheet > equity
60969000
Quarters > 3 > cash Flow > net Income
-7046000
Quarters > 3 > cash Flow > depreciation
274000
Quarters > 3 > cash Flow > change In Working Capital
857000
Quarters > 3 > cash Flow > cash From Operations
-9420000
Quarters > 3 > cash Flow > capital Expenditures
382
Quarters > 3 > cash Flow > cash From Investing
-618
Quarters > 3 > cash Flow > cash From Financing
-40000
Quarters > 3 > cash Flow > net Change In Cash
-10720000
Quarters > 3 > ratios > PE
-0.04499430038643827
Quarters > 3 > ratios > PB
5.661876910397087
Quarters > 3 > ratios > ROE
-11.449536649772837
Quarters > 3 > ratios > ROA
-9.138196098965832
Quarters > 3 > ratios > FCF
-9420382
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-8.851579501249695
Quarters > 3 > health Score
29
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
1088457
Annuals > 0 > income Statement > gross Profit
-1088457
Annuals > 0 > income Statement > operating Expenses
47364000
Annuals > 0 > income Statement > operating Income
-47364000
Annuals > 0 > income Statement > interest Expense
1370576
Annuals > 0 > income Statement > pretax Income
-43253000
Annuals > 0 > income Statement > net Income
-43253000
Annuals > 0 > income Statement > eps
-0.29239846729743557
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
147924852
Annuals > 0 > income Statement > income Tax Expense
18200
Annuals > 0 > income Statement > EBITDA
-40795000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
4111000
Annuals > 0 > balance Sheet > cash
69802000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
3250000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
74763000
Annuals > 0 > balance Sheet > property Plant Equipment
984000
Annuals > 0 > balance Sheet > total Assets
76390000
Annuals > 0 > balance Sheet > payables
2440000
Annuals > 0 > balance Sheet > short Term Debt
6242000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
15421000
Annuals > 0 > balance Sheet > equity
60969000
Annuals > 0 > cash Flow > net Income
-43253000
Annuals > 0 > cash Flow > depreciation
1088000
Annuals > 0 > cash Flow > change In Working Capital
-369000
Annuals > 0 > cash Flow > cash From Operations
-32834000
Annuals > 0 > cash Flow > capital Expenditures
699000
Annuals > 0 > cash Flow > cash From Investing
-699000
Annuals > 0 > cash Flow > cash From Financing
46147000
Annuals > 0 > cash Flow > net Change In Cash
12381000
Annuals > 0 > ratios > PE
-0.29239846729743557
Annuals > 0 > ratios > PB
4.4642642601978055
Annuals > 0 > ratios > ROE
-70.9426101789434
Annuals > 0 > ratios > ROA
-56.621285508574424
Annuals > 0 > ratios > FCF
-33533000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
29
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
10000000
Annuals > 1 > income Statement > cost Of Revenue
2574000
Annuals > 1 > income Statement > gross Profit
7426000
Annuals > 1 > income Statement > operating Expenses
35842000
Annuals > 1 > income Statement > operating Income
-28416000
Annuals > 1 > income Statement > interest Expense
2881000
Annuals > 1 > income Statement > pretax Income
-29998000
Annuals > 1 > income Statement > net Income
-29466000
Annuals > 1 > income Statement > eps
-0.22341212256346887
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
131890784
Annuals > 1 > income Statement > income Tax Expense
-532000
Annuals > 1 > income Statement > EBITDA
-26056000
Annuals > 1 > income Statement > operating Margin
-284.16
Annuals > 1 > income Statement > total Other Income Expense Net
-1582000
Annuals > 1 > balance Sheet > cash
57421000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
3732000
Annuals > 1 > balance Sheet > inventories
1247000
Annuals > 1 > balance Sheet > total Current Assets
63760000
Annuals > 1 > balance Sheet > property Plant Equipment
1650000
Annuals > 1 > balance Sheet > total Assets
66499000
Annuals > 1 > balance Sheet > payables
2346000
Annuals > 1 > balance Sheet > short Term Debt
652000
Annuals > 1 > balance Sheet > long Term Debt
4394000
Annuals > 1 > balance Sheet > total Liabilities
15962000
Annuals > 1 > balance Sheet > equity
50537000
Annuals > 1 > cash Flow > net Income
-29466000
Annuals > 1 > cash Flow > depreciation
1061000
Annuals > 1 > cash Flow > change In Working Capital
-1593000
Annuals > 1 > cash Flow > cash From Operations
-21132000
Annuals > 1 > cash Flow > capital Expenditures
419000
Annuals > 1 > cash Flow > cash From Investing
-419000
Annuals > 1 > cash Flow > cash From Financing
7973000
Annuals > 1 > cash Flow > net Change In Cash
-10761000
Annuals > 1 > ratios > PE
-0.22341212256346887
Annuals > 1 > ratios > PB
4.802007292874528
Annuals > 1 > ratios > ROE
-58.30579575360627
Annuals > 1 > ratios > ROA
-44.310440758507646
Annuals > 1 > ratios > FCF
-21551000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-2.1551
Annuals > 1 > health Score
29
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
1507000
Annuals > 2 > income Statement > cost Of Revenue
-257442
Annuals > 2 > income Statement > gross Profit
257442
Annuals > 2 > income Statement > operating Expenses
53924872
Annuals > 2 > income Statement > operating Income
-53667430
Annuals > 2 > income Statement > interest Expense
3361000
Annuals > 2 > income Statement > pretax Income
-44458642
Annuals > 2 > income Statement > net Income
-42121955
Annuals > 2 > income Statement > eps
-0.3491562172025876
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
120639281
Annuals > 2 > income Statement > income Tax Expense
-2336687
Annuals > 2 > income Statement > EBITDA
-39978656
Annuals > 2 > income Statement > operating Margin
-3561.2096881220973
Annuals > 2 > income Statement > total Other Income Expense Net
9208788
Annuals > 2 > balance Sheet > cash
68182000
Annuals > 2 > balance Sheet > short Term Investments
51104000
Annuals > 2 > balance Sheet > receivables
2748000
Annuals > 2 > balance Sheet > inventories
-2672000
Annuals > 2 > balance Sheet > total Current Assets
75197000
Annuals > 2 > balance Sheet > property Plant Equipment
2216000
Annuals > 2 > balance Sheet > total Assets
77413000
Annuals > 2 > balance Sheet > payables
3492000
Annuals > 2 > balance Sheet > short Term Debt
13890000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
26011000
Annuals > 2 > balance Sheet > equity
51402000
Annuals > 2 > cash Flow > net Income
-42220000
Annuals > 2 > cash Flow > depreciation
889000
Annuals > 2 > cash Flow > change In Working Capital
-2352000
Annuals > 2 > cash Flow > cash From Operations
-48821000
Annuals > 2 > cash Flow > capital Expenditures
13000
Annuals > 2 > cash Flow > cash From Investing
1987000
Annuals > 2 > cash Flow > cash From Financing
200000
Annuals > 2 > cash Flow > net Change In Cash
-59216000
Annuals > 2 > ratios > PE
-0.3491562172025876
Annuals > 2 > ratios > PB
4.318436579121435
Annuals > 2 > ratios > ROE
-81.9461402280067
Annuals > 2 > ratios > ROA
-54.41199152597109
Annuals > 2 > ratios > FCF
-48834000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-32.404777704047774
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
49213161
Annuals > 3 > income Statement > cost Of Revenue
24169298
Annuals > 3 > income Statement > gross Profit
25043863
Annuals > 3 > income Statement > operating Expenses
53299862
Annuals > 3 > income Statement > operating Income
-28255999.14
Annuals > 3 > income Statement > interest Expense
5222028
Annuals > 3 > income Statement > pretax Income
19220179
Annuals > 3 > income Statement > net Income
17174130
Annuals > 3 > income Statement > eps
0.1471216774869327
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
116734191
Annuals > 3 > income Statement > income Tax Expense
2046049
Annuals > 3 > income Statement > EBITDA
25486544
Annuals > 3 > income Statement > operating Margin
-57.41553390565585
Annuals > 3 > income Statement > total Other Income Expense Net
47476178
Annuals > 3 > balance Sheet > cash
126748887
Annuals > 3 > balance Sheet > short Term Investments
769470
Annuals > 3 > balance Sheet > receivables
1419000
Annuals > 3 > balance Sheet > inventories
-1820000
Annuals > 3 > balance Sheet > total Current Assets
134316469
Annuals > 3 > balance Sheet > property Plant Equipment
3421369
Annuals > 3 > balance Sheet > total Assets
170956225
Annuals > 3 > balance Sheet > payables
3090050
Annuals > 3 > balance Sheet > short Term Debt
841142
Annuals > 3 > balance Sheet > long Term Debt
14384000
Annuals > 3 > balance Sheet > total Liabilities
51949369
Annuals > 3 > balance Sheet > equity
119006856
Annuals > 3 > cash Flow > net Income
19220179
Annuals > 3 > cash Flow > depreciation
866466
Annuals > 3 > cash Flow > change In Working Capital
-2490080.17
Annuals > 3 > cash Flow > cash From Operations
-7070747.97
Annuals > 3 > cash Flow > capital Expenditures
722055.77
Annuals > 3 > cash Flow > cash From Investing
-568197.15
Annuals > 3 > cash Flow > cash From Financing
104802008
Annuals > 3 > cash Flow > net Change In Cash
95590736
Annuals > 3 > ratios > PE
0.1471216774869327
Annuals > 3 > ratios > PB
1.8048616580543897
Annuals > 3 > ratios > ROE
14.43121058504394
Annuals > 3 > ratios > ROA
10.045922574624
Annuals > 3 > ratios > FCF
-7792803.74
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-0.1583479618389073
Annuals > 3 > health Score
70
Valuation > metrics > PE
-0.0439029080188699
Valuation > metrics > PB
7.639306825400231
Valuation > final Score
20
Valuation > verdict
154.6% Overvalued
Profitability > metrics > ROE
-15.0736083093695
Profitability > metrics > ROA
-13.40278970366554
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.15030688012361046
Risk > metrics > Interest Coverage
-357.67857142857144
Risk > final Score
-1371
Risk > verdict
High
Liquidity > metrics > Current Ratio
41.07131661442006
Liquidity > metrics > Quick Ratio
41.07131661442006
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
21.911032385446312
Prev Valuations > 2
23.38123089602913
Prev Profitabilities > 0
0
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-1690
Prev Risks > 1
-189
Prev Risks > 2
-101
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T19:43:03.058Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-01
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
0.0014
Earnings History > 0 > eps Difference
-0.0014
Earnings History > 0 > surprise Percent
-100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-10
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.01
Earnings History > 1 > eps Estimate
0.0133
Earnings History > 1 > eps Difference
-0.0233
Earnings History > 1 > surprise Percent
-175.188
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-12
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.02
Earnings History > 2 > eps Estimate
-0.0243
Earnings History > 2 > eps Difference
0.0043
Earnings History > 2 > surprise Percent
17.6955
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-23
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.0151
Earnings History > 3 > eps Estimate
-0.011
Earnings History > 3 > eps Difference
-0.0041
Earnings History > 3 > surprise Percent
-37.2727
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-26
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.01
Earnings History > 4 > eps Estimate
-0.01
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
0
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-12
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.02
Earnings History > 5 > eps Estimate
-0.02
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
0
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-09-05
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.0862
Earnings History > 6 > eps Estimate
-0.01
Earnings History > 6 > eps Difference
-0.0762
Earnings History > 6 > surprise Percent
-762
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-15
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.0639
Earnings History > 7 > eps Estimate
-0.01
Earnings History > 7 > eps Difference
-0.0539
Earnings History > 7 > surprise Percent
-539
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-27
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
-0.015
Earnings History > 8 > eps Estimate
-0.02
Earnings History > 8 > eps Difference
0.005
Earnings History > 8 > surprise Percent
25
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-17
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-09-07
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.02
Earnings History > 10 > eps Estimate
-0.02
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
0
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-31
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-28
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.02
Earnings History > 12 > eps Estimate
-0.02
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
0
Earnings History > 13 > period
2021-06-30
Earnings History > 13 > report Date
2021-08-11
Earnings History > 13 > date
2021-06-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
0
Earnings History > 13 > eps Estimate
-0.14
Earnings History > 13 > eps Difference
0.14
Earnings History > 13 > surprise Percent
100
Earnings History > 14 > period
2021-03-31
Earnings History > 14 > report Date
2021-06-02
Earnings History > 14 > date
2021-03-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.1393
Earnings History > 14 > eps Estimate
-0.14
Earnings History > 14 > eps Difference
0.0007
Earnings History > 14 > surprise Percent
0.5
Earnings History > 15 > period
2020-12-31
Earnings History > 15 > report Date
2021-03-31
Earnings History > 15 > date
2020-12-31
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
0.0842
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
0.0842
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2020-09-30
Earnings History > 16 > report Date
2020-12-31
Earnings History > 16 > date
2020-09-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.2385
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-0.2385
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2020-06-30
Earnings History > 17 > report Date
2020-09-29
Earnings History > 17 > date
2020-06-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.225
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
-0.225
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2020-03-31
Earnings History > 18 > report Date
2020-06-15
Earnings History > 18 > date
2020-03-31
Earnings History > 18 > before After Market
AfterMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-3.277
Earnings History > 18 > eps Estimate
-0.26
Earnings History > 18 > eps Difference
-3.017
Earnings History > 18 > surprise Percent
-1160.3846
Earnings History > 19 > period
2019-12-31
Earnings History > 19 > report Date
2020-03-31
Earnings History > 19 > date
2019-12-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-3.2881
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
-3.2881
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2019-09-30
Earnings History > 20 > report Date
2019-12-31
Earnings History > 20 > date
2019-09-30
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.5867
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
-0.5867
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2019-06-30
Earnings History > 21 > report Date
2019-09-17
Earnings History > 21 > date
2019-06-30
Earnings History > 21 > before After Market
BeforeMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.5446
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
-0.5446
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2019-03-31
Earnings History > 22 > report Date
2019-04-29
Earnings History > 22 > date
2019-03-31
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.6985
Earnings History > 22 > eps Estimate
0
Earnings History > 22 > eps Difference
-0.6985
Earnings History > 22 > surprise Percent
-
Earnings History > 23 > period
2018-12-31
Earnings History > 23 > report Date
2019-03-31
Earnings History > 23 > date
2018-12-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.7163
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
-0.7163
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2018-09-30
Earnings History > 24 > report Date
2018-12-31
Earnings History > 24 > date
2018-09-30
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.6704
Earnings History > 24 > eps Estimate
0
Earnings History > 24 > eps Difference
-0.6704
Earnings History > 24 > surprise Percent
-
Earnings History > 25 > period
2018-06-30
Earnings History > 25 > report Date
2018-09-30
Earnings History > 25 > date
2018-06-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.6853
Earnings History > 25 > eps Estimate
0
Earnings History > 25 > eps Difference
-0.6853
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2018-03-31
Earnings History > 26 > report Date
2018-06-30
Earnings History > 26 > date
2018-03-31
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-0.7919
Earnings History > 26 > eps Estimate
0
Earnings History > 26 > eps Difference
-0.7919
Earnings History > 26 > surprise Percent
-
Earnings History > 27 > period
2017-12-31
Earnings History > 27 > report Date
2018-03-31
Earnings History > 27 > date
2017-12-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.8418
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
-0.8418
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2017-09-30
Earnings History > 28 > report Date
2017-12-31
Earnings History > 28 > date
2017-09-30
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-0.7654
Earnings History > 28 > eps Estimate
0
Earnings History > 28 > eps Difference
-0.7654
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2017-06-30
Earnings History > 29 > report Date
2017-09-30
Earnings History > 29 > date
2017-06-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
USD
Earnings History > 29 > eps Actual
-0.7596
Earnings History > 29 > eps Estimate
0
Earnings History > 29 > eps Difference
-0.7596
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2017-03-31
Earnings History > 30 > report Date
2017-06-30
Earnings History > 30 > date
2017-03-31
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
USD
Earnings History > 30 > eps Actual
-1.1018
Earnings History > 30 > eps Estimate
0
Earnings History > 30 > eps Difference
-1.1018
Earnings History > 30 > surprise Percent
-
Earnings History > 31 > period
2016-12-31
Earnings History > 31 > report Date
2017-03-31
Earnings History > 31 > date
2016-12-31
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
USD
Earnings History > 31 > eps Actual
-1.0598
Earnings History > 31 > eps Estimate
0
Earnings History > 31 > eps Difference
-1.0598
Earnings History > 31 > surprise Percent
-
Earnings History > 32 > period
2016-09-30
Earnings History > 32 > report Date
2016-12-31
Earnings History > 32 > date
2016-09-30
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
USD
Earnings History > 32 > eps Actual
-0.651
Earnings History > 32 > eps Estimate
0
Earnings History > 32 > eps Difference
-0.651
Earnings History > 32 > surprise Percent
-
Earnings History > 33 > period
2016-06-30
Earnings History > 33 > report Date
2016-09-30
Earnings History > 33 > date
2016-06-30
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
USD
Earnings History > 33 > eps Actual
-0.6848
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
-0.6848
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2016-03-31
Earnings History > 34 > report Date
2016-06-30
Earnings History > 34 > date
2016-03-31
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
USD
Earnings History > 34 > eps Actual
-1.9645
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
-1.9645
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2015-12-31
Earnings History > 35 > report Date
2016-03-31
Earnings History > 35 > date
2015-12-31
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
USD
Earnings History > 35 > eps Actual
-2.1283
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
-2.1283
Earnings History > 35 > surprise Percent
-
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APatterns Watch: How strong is Climb Bio Inc stock balance sheet - Weekly Trade Recap & Capital Protection Trading Alerts moha.gov.vn
Read more →Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
12/12/2025
Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) Defense World
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$7.1256
Analyst Picks
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 59.46% of the total shares of Mereo BioPharma Group PLC ADR
1.
HHG PLC(11.1181%)
since
2025/06/30
2.
Rubric Capital Management LP(9.6214%)
since
2025/06/30
3.
Mangrove Partners(5.4284%)
since
2025/06/30
4.
Deerfield Management Co(4.2178%)
since
2025/06/30
5.
Alkeon Capital Management, LLC(2.953%)
since
2025/06/30
6.
Rock Springs Capital Management LP(2.8066%)
since
2025/06/30
7.
683 Capital Management LLC(2.7342%)
since
2025/06/30
8.
Clearline Capital LP(2.2742%)
since
2025/06/30
9.
Goldman Sachs Group Inc(1.9423%)
since
2025/06/30
10.
Aberdeen Group PLC(1.9038%)
since
2025/06/30
11.
abrdn World Healthcare(1.8247%)
since
2025/07/31
12.
Tejara Capital Ltd(1.5276%)
since
2025/06/30
13.
abrdn Life Sciences Investors(1.3051%)
since
2025/08/31
14.
UBS (Lux) EF Biotech (USD) P-acc(1.0719%)
since
2025/05/31
15.
Renaissance Technologies Corp(0.9305%)
since
2025/06/30
16.
FMR Inc(0.9293%)
since
2025/06/30
17.
Fidelity Select Health Care(0.9249%)
since
2025/07/31
18.
Schonfeld Strategic Advisors LLC(0.5718%)
since
2025/06/30
19.
Fidelity Select Biotechnology(0.5355%)
since
2025/07/31
20.
Morgan Stanley - Brokerage Accounts(0.4936%)
since
2025/06/30
21.
Marshall Wace Asset Management Ltd(0.4826%)
since
2025/06/30
22.
Atle Fund Management AB(0.4808%)
since
2025/06/30
23.
Citadel Advisors Llc(0.4781%)
since
2025/06/30
24.
Fidelity Advisor Biotechnology I(0.4771%)
since
2025/07/31
25.
Fidelity Advisor Health Care I(0.4717%)
since
2025/07/31
26.
Two Sigma Investments LLC(0.4143%)
since
2025/06/30
27.
Soleus Capital Management, L.P.(0.3769%)
since
2025/06/30
28.
HealthInvest Sustainable Healthcare E(0.3376%)
since
2025/07/31
29.
iShares Genomics Immnlgy & Hlthcr ETF(0.2252%)
since
2025/08/31
30.
Healthlnvest S&M Cap Healthcare C(0.1432%)
since
2025/07/31
31.
Fidelity VIP Health Care Initial(0.1287%)
since
2025/07/31
32.
UBS Global Equity Biotech(0.0805%)
since
2025/06/30
33.
SPDR® S&P® International Small Cap ETF(0.0704%)
since
2025/08/29
34.
Fidelity Nasdaq Composite Index(0.0582%)
since
2025/07/31
35.
Arctic Aurora LifeScience I(0.0349%)
since
2025/07/31
36.
Virtus LifeSci Biotech Clinical Trls ETF(0.0277%)
since
2025/08/29
37.
Avanza Healthcare by Samuelsson & Hult(0.024%)
since
2025/08/31
38.
ActivePassive International Equity ETF(0.0174%)
since
2025/08/29
39.
Forefront Tiresias Strategy(0.012%)
since
2025/06/30
40.
iShares Genomics Imnlgy & Hlthcr ETF CAD(0.0069%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
0.0014
Date
2025-09-30
EPS Actual
-0.01
EPS Estimate
0.0133
EPS Difference
-0.0233
Surprise Percent
-175.188%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.